General Comments / Chat, page-6331

Unfortunately Everyone I've put into RAC is currently bleeding.

Although I'm still buying small parcels I won't be recommending it further. I have a couple of personal concerns which I'm willing to sit on until our new CEO takes over and our new director gets some traction. Personally the buyback has been disappointing, I have no idea, which may be the point, of the boards perception of value, it was originally above $2 then it was $2 and now I don't know if it still exists or the money is going elsewhere. We made a 500k u.s.donation which wasn't from our clinical funds raised and came from left field. The funds we as shareholders raised is now 12 months old, I may be expecting to much but I expected more than was delivered this past year. I'm hoping 2023 is full of uplifting news and we can hurry up and get zantrene into patients in critical need.